Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?

AbbVie posted Q2 net revenue of just under $17B, up more than 10% YoY, with double-digit growth in immunology (+15%) and neuroscience (>20%) despite a ~2% decline in oncology. The article argues AbbVie’s headline valuation (P/E nearly 70) is overstated due to acquisition-related expenses, pointing to a much lower forward P/E around 18. It also highlights a 2.8% dividend yield, suggesting the stock may be a modestly attractive value for long-term investors.

Analysis

ABBV reads more like a cash-flow normalization story than a classic high-multiple growth name. The market is likely underappreciating how much reported earnings are being suppressed by non-operating noise; if that drag continues to roll off, the stock can rerate without needing heroic revenue acceleration. For a large-cap healthcare name, sustained low-double-digit top-line growth plus capital return is enough to pull in marginal buyers from both income and quality-growth mandates.

The competitive implication is that ABBV is quietly taking share in the parts of pharma investors actually pay for: durable immunology franchises and emerging CNS exposure. That puts pressure on slower-growth peers with less visible organic momentum and weaker dividend support, especially names that rely more on buyback math than revenue quality. In the sector, ABBV looks like a relative-value winner versus PFE; if the market continues to reward visible growth and penalize execution risk, that gap should widen over the next 1-3 quarters.

The contrarian risk is that the stock may already be close to fairly valued if growth normalizes just a bit below current expectations. The setup breaks if revenue growth slips back into the mid-single digits, if margins fail to improve as the acquisition noise fades, or if management uses cash flow for deal-making instead of buybacks/dividend growth. Near term, the catalyst is not the headline quarter itself but the next guidance reset and whether consensus raises forward EPS; over 6-18 months, the key is whether the market is willing to pay a market multiple for a pharma company with above-average growth and a 2.8% yield.

Key Decisions for Investors

• Long ABBV on pullbacks over the next 1-3 weeks; target a 6-12 month rerating to ~20-22x forward earnings if growth holds and reported EPS noise fades. Falsify if forward revenue growth drops below ~8% or management trims full-year guidance.
• Pair trade: long ABBV / short PFE for a 1-3 quarter relative-value expression. Thesis: ABBV has better organic growth visibility and capital-return support; cover if PFE shows a credible pipeline-led reacceleration or ABBV guidance disappoints.
• Use ABBV as a defensive-growth overweight versus XLV on any sector weakness. This is a relative-quality trade, not a market beta call; exit if healthcare defensives re-rate broadly and the spread closes.
• For upside convexity, consider a 6-12 month call spread on ABBV only if you expect multiple expansion rather than fundamental surprise. Best strike selection is a modest out-of-the-money structure; avoid outright calls unless implied vol pulls back.
• Watch the next earnings/guidance print for free-cash-flow conversion and capital deployment. If buyback pace accelerates while growth stays double-digit, that is the cleanest setup for a follow-on leg higher.